These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37997863)

  • 1. Nosocomial pneumonia: Current etiology and impact on antimicrobial therapy.
    Gamazo JJ; Candel FJ; González Del Castillo J
    Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):9-14. PubMed ID: 37997863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia.
    Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
    Obritsch MD; Fish DN; MacLaren R; Jung R
    Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane-tazobactam in nosocomial pneumonia.
    Candel FJ; González Del Castillo J; Julián Jiménez A; Matesanz M
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):35-39. PubMed ID: 35488823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study.
    Motbainor H; Bereded F; Mulu W
    BMC Infect Dis; 2020 Jan; 20(1):92. PubMed ID: 32000693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia.
    Motos A; Yang H; Yang M; Torres A
    Expert Opin Pharmacother; 2019 Aug; 20(12):1439-1448. PubMed ID: 31095426
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative study of the etiology of nosocomial bacteremic pneumonia in ventilated and non-ventilated patients: a 10-year experience in an institution.
    Bouza E; Guillen-Zabala H; Rojas A; Cañada G; Cercenado E; Sánchez-Carrillo C; Díez C; Puente L; Muñoz P; Galar A
    Microbiol Spectr; 2023 Dec; 11(6):e0151723. PubMed ID: 37698391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
    Dupont H; Marciniak S; Zogheib E; Mammeri H; Friggeri A; Ammenouche N; Levrard M; Airapetian N; Tinturier F; Mahjoub Y
    Anaesth Crit Care Pain Med; 2015 Jun; 34(3):141-4. PubMed ID: 26004874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of Antimicrobial Resistance among Pseudomonas aeruginosa: Implications for Therapy.
    Lynch JP; Zhanel GG; Clark NM
    Semin Respir Crit Care Med; 2017 Jun; 38(3):326-345. PubMed ID: 28578556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic Guidelines for Critically Ill Patients in Nigeria.
    Oladele RO; Ettu AO; Medugu N; Habib A; Egbagbe E; Osinaike T; Makanjuola OB; Ogunbosi B; Irowa OO; Ejembi J; Uwaezuoke NS; Adeleke G; Mutiu B; Ogunsola F; Rotimi V
    West Afr J Med; 2023 Sep; 40(9):962-972. PubMed ID: 37768104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study.
    Chen CY; Yang KY; Peng CK; Sheu CC; Chan MC; Feng JY; Wang SH; Chen CM; Zheng ZR; Liang SJ; Lin YC;
    Sci Rep; 2022 May; 12(1):7501. PubMed ID: 35525867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study.
    Mekonnen H; Seid A; Molla Fenta G; Gebrecherkos T
    PLoS One; 2021; 16(11):e0257272. PubMed ID: 34780494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin.
    Hamer DH
    Am J Respir Crit Care Med; 2000 Jul; 162(1):328-30. PubMed ID: 10903263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.
    Micek ST; Kollef MH; Torres A; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Wunderink R; Menichetti F; Schramm G; Menon V
    Infect Control Hosp Epidemiol; 2015 Oct; 36(10):1190-7. PubMed ID: 26190444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic guidelines for Pseudomonas aeruginosa infections.
    Giamarellou H
    Int J Antimicrob Agents; 2000 Oct; 16(2):103-6. PubMed ID: 11053788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by Pseudomonas aeruginosa.
    Albin OR; Pogue JM; Wunderink RG; Kaye KS
    Clin Microbiol Infect; 2024 Feb; 30(2):162-164. PubMed ID: 37429434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.